Introduction: Ovarian cancer is the leading cause of death from gynecologic cancers, in
fact,> 80% of cases are diagnosed as advanced-stage disease associated with a high …

Simple Summary There are currently no blood biomarkers approved for routine clinical use
in endometrial cancer. Serum human epididymis protein 4 (HE4) is significantly higher in …

Effective treatment of ovarian cancer depends upon the early detection of the malignancy.
Here, we report on the development of a new nanostructured immunosensor for early …

Objective We evaluated the diagnostic performance of CA 125, HE 4, and ROMA for ovarian
cancer in Koreans and set optimal cutoffs. Method Serum levels of HE 4 and CA 125 and the …

The objectives of this study are to establish reference limits for human epididymis protein 4,
HE4, and investigate factors influencing HE4 levels in healthy subjects. HE4 was measured …

Background: The aim of this work was to analyze the diagnostic and prognostic value of
serum human epididymis protein 4 (HE4) and Risk for Ovarian Malignancy Algorithm …

Epithelial ovarian cancer has become the most frequent cause of deaths among
gynecologic malignancies. Our study elucidates the diagnostic performance of Risk of …

Ovarian cancer is a primary gynecological malignancy with a global 5-year survival rate of
44%. The majority of patients present with advanced disease at initial diagnosis because of …

Abstract Backgrounds Risk for Ovarian Malignancy Algorithm (ROMA) and Human
epididymis protein 4 (HE4) appear to be promising predictors for epithelial ovarian cancer …

Background: Human epididymis protein 4 (HE4) is described as a useful new biomarker in
ovarian cancer. As HE4 is neither tumor nor organ specific, we intensively investigated the …